These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36612009)

  • 21. The management of ductal carcinoma in situ (DCIS). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Association of Radiation Oncologists.
    CMAJ; 1998 Feb; 158 Suppl 3():S27-34. PubMed ID: 9484276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience.
    van der Noordaa MEM; Ioan I; Rutgers EJ; van Werkhoven E; Loo CE; Voorthuis R; Wesseling J; van Urk J; Wiersma T; Dezentje V; Vrancken Peeters MTFD; van Duijnhoven FH
    Ann Surg Oncol; 2021 Nov; 28(12):7383-7394. PubMed ID: 33978889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.
    Pawloski KR; Tadros AB; Sevilimedu V; Newman A; Gentile L; Zabor EC; Morrow M; Van Zee KJ; Kirstein LJ
    Breast Cancer Res Treat; 2021 Apr; 186(3):617-624. PubMed ID: 33675490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ductal Carcinoma In Situ - Quo Vadis?
    Peltecu G
    Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.
    Kuerer HM; Rauch GM; Krishnamurthy S; Adrada BE; Caudle AS; DeSnyder SM; Black DM; Santiago L; Hobbs BP; Lucci A; Gilcrease M; Hwang RF; Candelaria RP; Chavez-MacGregor M; Smith BD; Arribas E; Moseley T; Teshome M; Miggins MV; Valero V; Hunt KK; Yang WT
    Ann Surg; 2018 May; 267(5):946-951. PubMed ID: 28549010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of residual ductal carcinoma in situ with breast cancer treatment outcomes after neoadjuvant chemotherapy according to hormone receptor status.
    Shin E; Yoo TK; Kim J; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Lee SB
    Discov Oncol; 2024 Jul; 15(1):288. PubMed ID: 39017974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance characteristics of specimen radiography for margin assessment for ductal carcinoma in situ: a systematic review.
    Versteegden DPA; Keizer LGG; Schlooz-Vries MS; Duijm LEM; Wauters CAP; Strobbe LJA
    Breast Cancer Res Treat; 2017 Dec; 166(3):669-679. PubMed ID: 28831674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.
    Kim YS; Chang JM; Moon HG; Lee J; Shin SU; Moon WK
    Ann Surg Oncol; 2016 Apr; 23(4):1135-42. PubMed ID: 26628432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local treatment options for young women with ductal carcinoma in situ: A systematic review and meta-analysis comparing breast conserving surgery with or without adjuvant radiotherapy, and mastectomy.
    Chien JC; Liu WS; Huang WT; Shih LC; Liu WC; Chen YC; Chou KJ; Shiue YL; Lin PC
    Breast; 2022 Jun; 63():29-36. PubMed ID: 35299032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
    Golshan M; Cirrincione CT; Sikov WM; Carey LA; Berry DA; Overmoyer B; Henry NL; Somlo G; Port E; Burstein HJ; Hudis C; Winer E; Ollila DW;
    Breast Cancer Res Treat; 2016 Nov; 160(2):297-304. PubMed ID: 27704226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-operative radiotherapy for ductal carcinoma in situ of the breast.
    Goodwin A; Parker S; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2009 Jul; (3):CD000563. PubMed ID: 19588320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer.
    Labrosse J; Morel C; Lam T; Laas E; Feron JG; Coussy F; Lae M; Reyal F; Hamy AS
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ductal Carcinoma In Situ (DCIS) at Breast MRI: Predictors of Upgrade to Invasive Carcinoma.
    Lamb LR; Lehman CD; Oseni TO; Bahl M
    Acad Radiol; 2020 Oct; 27(10):1394-1399. PubMed ID: 31699638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and management of ductal carcinoma in situ (DCIS).
    Virnig BA; Shamliyan T; Tuttle TM; Kane RL; Wilt TJ
    Evid Rep Technol Assess (Full Rep); 2009 Sep; (185):1-549. PubMed ID: 20629475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-operative radiotherapy for ductal carcinoma in situ of the breast.
    Goodwin A; Parker S; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2013 Nov; (11):CD000563. PubMed ID: 24259251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-operative radiotherapy for ductal carcinoma in situ of the breast.
    Goodwin A; Parker S; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2009 Oct; (4):CD000563. PubMed ID: 19821272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Revisit the practice of lymph node biopsy in patients diagnosed as ductal carcinoma in situ before operation: a retrospective analysis of 682 cases and evaluation of the role of breast MRI.
    Lai HW; Chang YL; Chen ST; Chang YJ; Wu WP; Chen DR; Kuo SJ; Liao CY; Wu HK
    World J Surg Oncol; 2021 Sep; 19(1):263. PubMed ID: 34470633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.